Imatinib Withdrawn Phase 2 Trials for Chronic Myelogenous Leukemia (CML) Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT01011998A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML)